The FDA has removed the REMS program requirements for embryofetal toxicity risk from all endothelin receptor antagonist medications.

Travere Therapeutics, Inc. (NASDAQ:TVTX) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts.

Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.

SAN DIEGO, June 03, 2025--Travere Therapeutics today announced that the Company will present seven abstracts at the upcoming ERA Congress in Vienna, Austria, in June.

Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 62nd ERA Congress Data from SPARTACUS and PROTECT OLE to show significant proteinuria reduction when replacing RASi with ...

Investing.com -- Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) rose 7% following the company's announcement of its intent to submit a supplemental New Drug Application (sNDA) for FILSPARI ...

FILSPARI holds strong market potential as the first FDA-approved non-immunosuppressive therapy for IgA nephropathy, a rare kidney disease with significant unmet needs. As more patients and ...

FILSPARI holds strong market potential as the first FDA-approved non-immunosuppressive therapy for IgA nephropathy, a rare kidney disease with significant unmet needs. As more patients and providers ...

FILSPARI is already approved for slowing kidney function decline in adults with IgA nephropathy (IgAN) and could become the first FDA-approved treatment for FSGS if approved. Additionally, Travere ...

FILSPARI is already approved for slowing kidney function decline in adults with IgA nephropathy (IgAN) and could become the first FDA-approved treatment for FSGS if approved.

If approved, FILSPARI would be the first and only FDA-approved treatment for FSGS, a rare kidney condition and a leading cause of kidney failure SAN DIEGO, May 15, 2025--(BUSINESS WIRE)--Travere ...